Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
Diabetes Obes Metab
; 24(8): 1553-1564, 2022 08.
Article
in En
| MEDLINE
| ID: mdl-35441470
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Cardiovascular Diseases
/
Weight Gain
/
Glucagon-Like Peptides
Type of study:
Clinical_trials
/
Risk_factors_studies
Limits:
Adult
/
Humans
Language:
En
Journal:
Diabetes Obes Metab
Journal subject:
ENDOCRINOLOGIA
/
METABOLISMO
Year:
2022
Document type:
Article
Affiliation country:
United kingdom
Country of publication:
United kingdom